Latest Content

Drs. Nunnery and McCann discuss the evolving HER2-positive breast cancer treatment paradigm in the latest episode of “Breast Cancer Briefing.”

FDA approves a PD-L1 test to help identify patients with esophageal or gastroesophageal junction (GEJ) cancer who may benefit from Keytruda.

Dr. Christopher H. Lieu highlights the rising cancer rate in younger adults and the need for more personalized, comprehensive care strategies.

New NCCN guidelines highlight how structured exercise and molecular profiling significantly reduce recurrence rates.

Experts highlight rising cancer rates in younger adults and the need for tailored support, treatment and survivorship care across the continuum.

Hernexeos led to high response rates and disease control in HER2-mutant NSCLC, including patients with brain metastases, with manageable safety.

I struggle sometimes, wondering, “Why me?” and “Why testicular cancer?” Was God telling me something? Maybe to slow down and let him take control. So, I try my best to let go.

Amanda discusses the hidden challenges of chronic GVHD and how advocacy and storytelling help her support others facing similar struggles.

Tagrisso combined with chemotherapy improved how long patients with EGFR- and TP53-mutant NSCLC lived without their cancer worsening compared with Tagrisso alone.

So many friends I have met along the way wanted so badly to live and they weren't able to. They didn't lose and I didn't win. We all walked through something really hard and got different outcomes.

In the phase 3 ATHENA-MONO trial, 5-year data show Rubraca helped delay cancer worsening in advanced ovarian cancer vs placebo.

A living liver donor shares recovery challenges, emotional rewards and advice for those considering donation to help save a life.

KRAS G12d-targeted protein degrader setidegrasib demonstrated antitumor activity and a manageable safety profile in patients with KRAS G12d-mutant non–small cell lung cancer.